Predictive biomarkers in the development of oncology drugs: A therapeutic industry perspective

Clinical Pharmacology and Therapeutics

Volumn 85, Issue 5, 2009, Pages 535-538

  Fine, B M ^a   Amler, L ^a  

^a GENENTECH INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BCR ABL PROTEIN; BIOLOGICAL MARKER; CELL SURFACE RECEPTOR; CETUXIMAB; DASATINIB; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERLOTINIB; ESTROGEN RECEPTOR; GEFITINIB; GLUCURONOSYLTRANSFERASE 1A1; HER3 PROTEIN; HER4 PROTEIN; IMATINIB; IRINOTECAN; LENALINOMIDE; MERCAPTOPURINE; NILOTINIB; PANITUMUMAB; PROGESTERONE RECEPTOR; STEM CELL FACTOR RECEPTOR; TRASTUZUMAB; UNCLASSIFIED DRUG; WARFARIN;

BIOTECHNOLOGY; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER RESEARCH; CANCER THERAPY; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; COLORECTAL CANCER; DRUG INDUSTRY; GASTROINTESTINAL STROMAL TUMOR; HIGH THROUGHPUT SCREENING; HUMAN; LEUKEMIA; LUNG NON SMALL CELL CANCER; METASTASIS; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL; REVIEW;

ANTINEOPLASTIC AGENTS; DRUG DELIVERY SYSTEMS; DRUG DESIGN; HUMANS; NEOPLASMS; RECEPTOR, EPIDERMAL GROWTH FACTOR; TUMOR MARKERS, BIOLOGICAL;

EID: 67349111010     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2009.9     Document Type: Review

References (25)

1. Hirschhorn, J.N. & Daly, M.J. Genome-wide association studies for common diseases and complex traits. Nat. Rev. Genet. 6, 95-108 (2005).
2. Liotta, L.A., Ferrari, M. & Petricoin, E. Clinical proteomics: written in blood. Nature 425, 905 (2003).
3. Perou, C.M. et al. Molecular portraits of human breast tumours. Nature 406, 747-752 (2000).
4. Hudis, C.A. Trastuzumab - mechanism of action and use in clinical practice. N. Engl. J. Med. 357, 39-51 (2007).
5. Slamon, D.J., Clark, G.M., Wong, S.G., Levin, W.J., Ullrich, A. & McGuire, W.L. Human breast cancer: correlation of relapse and survival with amplifcation of the HER-2/neu oncogene. Science 235, 177-182 (1987).
6. Lewis, G.D. et al. Diferential responses of human tumor cell lines to anti-p185HER2 monoclonal antibodies. Cancer Immunol. Immunother. 37, 255-263 (1993).
7. Slamon, D.J. et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med. 344, 783-792 (2001).
8. Romond, E.H. et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N. Engl. J. Med. 353, 1673-1684 (2005).
9. Jonker, D.J. et al. Cetuximab for the treatment of colorectal cancer. N. Engl. J. Med. 357, 2040-2048 (2007).
10. Van Cutsem, E. et al. Randomized phase III study of irinotecan and 5-FU/ FA with or without cetuximab in the frst-line treatment of patients with metastatic colorectal cancer (mCRC): the CRYSTAL trial. J. Clin. Oncol. 25 (18 suppl.), Abstract 4000 (2007).
11. Chung, K.Y. et al. Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. J. Clin. Oncol. 23, 1803-1810 (2005).
12. Khambata-Ford, S. et al. Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. J. Clin. Oncol. 25, 3230-3237 (2007).
13. Karapetis, C.S. et al. K-ras mutations and beneft from cetuximab in advanced colorectal cancer. N. Engl. J. Med. 359, 1757-1765 (2008).
14. Van Cutsem, E. et al. KRAS status and efcacy in the frst-line treatment of patients with metastatic colorectal cancer (mCRC) treated with FOLFIRI with or without cetuximab: the CRYSTAL experience. J. Clin. Oncol. 26 (suppl.), 2 (2008).
15. Amado, R.G. et al. Wild-type KRAS is required for panitumumab efcacy in patients with metastatic colorectal cancer. J. Clin. Oncol. 26, 1626-1634 (2008).
16. Lynch, T.J. et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to geftinib. N. Engl. J. Med. 350, 2129-2139 (2004).
17. Pao, W. et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to geftinib and erlotinib. Proc. Natl. Acad. Sci. USA 101, 13306-13311 (2004).
18. Tsao, M.S. et al. Erlotinib in lung cancer - molecular and clinical predictors of outcome. N. Engl. J. Med. 353, 133-144 (2005).
19. Zhu, C-Q. et al. Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21. J. Clin. Oncol. 26, 4268-4275 (2008).
20. Eberhard, D.A. et al. Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J. Clin. Oncol. 23, 5900-5909 (2005).
21. Wolf, A.C. et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J. Clin. Oncol. 25, 118-145 (2007).
22. Paik, S. et al. Beneft from adjuvant trastuzumab may not be confned to patients with IHC 3+ and/or FISH-positive tumors: central testing results from NSABP B-31. J. Clin. Oncol. 25 (suppl.), 511 (2007).
23. Biomarkers Defnitions Working Group. Biomarkers and surrogate endpoints: preferred defnitions and conceptual framework. Clin. Pharmacol. Ther. 69, 89-95 (2001).
24. McClatchey, K.D. Clinical Laboratory Medicine 2nd edn. (Lippincott Williams & Wilkins: Philadelphia, 2002).
25. Minamoto, T., Mai, M. & Ronai, Z. K-ras mutation: early detection in molecular diagnosis and risk assessment of colorectal, pancreas, and lung cancers - a review. Cancer Detect. Prev. 24, 1-12 (2000).